Quantitative, Multidimensional Immune Biomarkers

from only 2 sections of solid tumor FFPE tissue

“ImmunoPrism’s release represents years of technology development and validation work to move molecular profiling of cancer tissues out of the analog approaches that persist today, and into the digital world.” said Dr. Jarret Glasscock, Chief Executive Officer of Cofactor Genomics.


“The cancer immune cycle is complex, necessitating sensitive and robust RNA-based technologies to inform treatment decisions. Technologies like Cofactor ImmunoPrism will facilitate current drug development and fuel the future of precision medicine”

Cancer's Immune Cycle

Comprehensive, quantitative immune characterization is key to understanding disease.
Cofactor’s ImmunoPrism assay reports on the most impactful immune modulatory molecules demonstrated to have implications in drug discovery, biomarker development, and immunotherapy efficacy monitoring. 

Measure TILs from FFPE

Only two FFPE sections required


immune cell + escape gene

solid tumor microenvironment profiling

Version: 1.1
reports on 8 major cell types + expression of 10 key immune checkpoint molecules


with multidimensional biomarker analysis included

Cofactor Genomics introduces ImmunoPrism, an RNA-based immune profiling assay which enables a unique look into an oncology patient’s immune profile – far beyond traditional “hot” or “cold” classification.


Clinical archives and samples such as FFPE, FNAs, CNBs, and LCM solid tumors have previously been difficult to characterize.  ImmunoPrism accommodates these valuable and degraded materials with very low inputs and provides extensive immune characterization beyond current technologies – including differentiating cells such as M1 and M2 macrophages and Tregs – with high confidence. Find new biomarkers or improve patient selection as you transition from translational to clinical research applications.


Submit your samples to Cofactor and we’ll deliver a fully-analyzed data set highlighting immune escape genes and immune cell profiles, in one easy-to-interpret report. Don’t settle for qualitative, generic characterization from disparate assays such as IHC, flow cytometry, or expression arrays.  Gain novel immune insights quickly and confidently.


Cofactor’s ImmunoPrism Assay is offered both for Research Use Only (not be used as a diagnostic assay) and as a CAP-validated assay. Please Contact Us to discuss which option is right for your application.

Now offered as a CAP/CLIA clinically-validated assay.

Combining multiple immune and escape analytes into a multidimensional biomarker, ImmunoPrism delivers an turnkey biomarker solution with increased predictive power over individual analytes.

Total RNA and other tissue types including fresh, frozen, FNAs, CNBs, and LCM samples also accepted.
Featured Immune Cells

CD4+ T cells, CD8+ T cells, CD19+ B cells, CD14+ Monocytes, CD56+ NK cells, M1 Macrophages, M2 Macrophages, Treg cells

Featured Escape Genes

PD-1, PD-L1, CTLA4, OX40, TIM-3, BTLA, ICOS, CD47, IDO1, ARG1

Don’t see your gene or immune marker of interest? Let us know.

Download the Data Sheet with validation data and applications

Discuss your specific application of ImmunoPrism
with our Project Scientist team.

Translational Immune Profiling Assays

Product NameCatalog NumberDescriptionPrice per Sample
ImmunoPrism AssayCFGDX-301Individual immune report including gene expression for 8 cell types and 10 immune inhibitory molecules plus multidimensional biomarker report for sample cohortsContact Us
CAP-validated AssayCFGDX-501Clinically-validated immune cell reportContact Us
 Contact [email protected] to learn more. 

The ImmunoPrism assay was developed and characterized by Cofactor Genomics in San Francisco, CA. ImmunoPrism is offerred for Research Use Only (RUO) and as a CAP/CLIA validated clinical assay. The RUO assay is not for use in diagnostics procedures. The results of the included report are generated by a specific ImmunoPrism Version and are subject to change in future releases. Gene expression levels of escape genes are calculated for the sample in comparison to mean expression across various cancers. Immune profiling in ImmunoPrism has been shown to significantly correlate with flow cytometry measurements for PBMC samples across 5 different immune cell types. In addition, ImmunoPrism immune profiling has also shown to be consistent across fresh-frozen and formalin-fixed samples. Furthermore, ImmunoPrism immune profiling has been validated in dissociated tumor cells. For technical support or additional information on assay performance or validation, please contact: [email protected]



We value our collaborators and partners who are helping to demonstrate the power of immune profiling.

Seth M. Pollack, MD

Seth M. Pollack, MD

Dr. Seth M. Pollack is an expert on sarcomas, cancers of the bone & soft tissues. Learn more about our collaboration in this
GenomeWeb webinar, available for download.



Are you looking for CAP/CLIA-validated RNA assays?

Contact us to ensure you’re meeting regulatory guidelines with our CAP/CLIA offerings.

Learn more about our discovery RNA-seq offerings.

Start typing and press Enter to search